Obesity
Conditions
Keywords
overweight
Brief summary
NNC0487-0111 is a new medicine similar to 2 hormones that are produced in human body: amylin and glucagon-like peptide-1 (GLP-1). Both hormones work like body's own hormones and help the body to feel full. This study tests if the study medicine is safe and to find out how the medicine works in humans. This study also look at how the study medicine affects body weight and how to improve the treatment of people with overweight, obesity or related diseases. This study will have 4 parts: Part A, B, C and D. Part A: This is planned to consist of five groups, one additional group may be added. Each group will include 8 participants, with 6 participants being randomised to receive a single dose of NNC0487-0111 A and 2 participants randomised to receive placebo. The dosing within each group will be sequential, i.e., 2 sentinel participants (1 on active and 1 on placebo). Part B: This is planned to consist of three groups, one additional group may be added. Each group will include 12 participants, with 9 participants being randomised to receive NNC0487-0111 A and 3 participants randomised to receive placebo once daily for 10 days. The dosing within each group will be sequential. For the first group, 4 sentinel participants (3 on active and 1 on placebo) will be dosed followed by a safety observation period of 7 days (168 hours), before dosing of the remaining participants in the group will be initiated. For the remaining groups, 4 sentinel participants (3 on active and 1 on placebo) will be dosed followed by a safety observation period of at least 36 hours before dosing of the remaining participants in the group will be initiated. Part C and D are matching regarding planned visits and procedures, but the study interventions in Part D (NNC0487-0111 B) differ from Part A, B and C (NNC0487-0111 A). Each part is planned to consist of one group, although one additional group may be added. Each group will include 20 participants, with 16 participants being randomised to receive active treatment and 4 participants randomised to receive placebo once-daily for 12 weeks. The dosing will be sequential, i.e., 4 sentinel participants (3 on active and 1 on placebo) will be dosed followed by a safety observation period of at least 36 hours before dosing of the remaining participants in the cohort will be initiated. The remaining participants will be dosed in smaller groups of 8 participants separated by a safety observation period of at least 36 hours. A safety evaluation will be made between dosing of participants within a group and before moving on to a higher dose.
Interventions
DRUGNNC0487-0111 A
Participants will receive NNC0487-0111 A tablet once daily.
DRUGNNC0487-0111 B
Participants will receive NNC0487-0111 B tablet once daily.
OTHERPlacebo B (NNC0487-0111 B)
Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
OTHERPlacebo A (NNC0487-0111 A)
Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Part A and B: * Male or female aged 18-55 years (both inclusive) at time of signing informed consent * Body mass index (BMI) of 25.0 to 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Part C and D: * Male or female aged 18-55 years (both inclusive) at time of signing informed consent * Body mass index (BMI) of 27.0 to 39.9 kg/m\^2 (both inclusive) at screening * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion criteria
Part A and B: * Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol * HbA1c greater than or equal to 6.5 % (48 millimoles per mole (mmol/mol)) at screening * Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values * Vitamin D (25-hydroxycholecalciferol) less than 20 Nanograms per milliliter (ng/mL) (50 nano molar (NM)) at screening * Parathyroid hormone (PTH) outside normal range at screening * Total calcium outside normal range at screening * Amylase greater than or equal to 2 times upper limit of normal at screening * Lipase greater than or equal to 2 times upper limit of normal at screening Part C and D: * Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol * HbA1c greater than or equal to 6.5 % (48 mmol/mol) at screening * Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: * Vitamin D (25-hydroxycholecalciferol) less than 20 ng/mL (50 nM) at screening * Parathyroid hormone (PTH) outside normal range at screening * Total calcium outside normal range at screening * Amylase greater than or equal to 2 times upper limit of normal at screening * Lipase greater than or equal to 2 times upper limit of normal at screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of treatment emergent adverse events (TEAE) | Part A: From pre-dose on Day 1 to 22 days; Part B: From pre-dose on Day 1 to 31 days; Part C and D: From pre-dose on Day 1 to 105 days | Number of events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose | From pre-dose on Day 1 until completion of the end of study visit (Day 22) | Hours\*Nanomoles per liter (h\*nmol/L) |
| Part A: Cmax,SD; the maximum plasma concentration of NNC0487- 0111 after a single dose | From pre-dose on Day 1 until completion of the end of study visit (Day 22) | Nanomoles per liter (nmol/L) |
| Part C and D: AUC0-24h,MD; the area under the NNC0487-011 plasma concentration-time curve from time 0 to 24 hours after last multiple dose | From pre-dose on Day 84 until Day 85 (24 hours post-dose) | h\*nmol/L |
| Part B: AUC0-24h,MD; the area under the NNC0487-011 plasma concentration-time curve from time 0 to 24 hours after last multiple dose | From pre-dose on Day 10 until Day 11 (24 hours post-dose) | h\*nmol/L |
| Part B: Cmax,MD; the maximum plasma concentration of NNC0487- 0111 after last multiple dose | From pre-dose on Day 10 until Day 22 | nmol/L |
| Part C and D: Cmax,MD; the maximum plasma concentration of NNC0487- 0111 after last multiple dose | From pre-dose on Day 84 until completion of the end of study visit (Day 105) | nmol/L |
Countries
United States
Outcome results
None listed